Ftse Mib
32.665,21
-2,81%
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
NASDAQ
17.688,88
0,12%
Bitcoin
66.581,10
0,59%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ PMV Pharmaceuticals Inc (PMVP) PMV Pharmaceuticals Inc (PMVP) Notizie

PMVP

PMV Pharmaceuticals (PMVP)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PMVP
DataOraFonteTitoloSimboloCompagnia
10/06/202422:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PMVPPMV Pharmaceuticals Inc
07/06/202414:32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PMVPPMV Pharmaceuticals Inc
30/05/202413:00GlobeNewswire Inc.PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in JuneNASDAQ:PMVPPMV Pharmaceuticals Inc
29/05/202413:00Business WireFoundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C ReactivatorNASDAQ:PMVPPMV Pharmaceuticals Inc
09/05/202414:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PMVPPMV Pharmaceuticals Inc
09/05/202414:00GlobeNewswire Inc.PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
27/03/202413:00GlobeNewswire Inc.PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid TumorsNASDAQ:PMVPPMV Pharmaceuticals Inc
18/03/202421:01GlobeNewswire Inc.PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s CancerNASDAQ:PMVPPMV Pharmaceuticals Inc
29/02/202422:01GlobeNewswire Inc.PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
26/02/202414:00GlobeNewswire Inc.PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care ConferenceNASDAQ:PMVPPMV Pharmaceuticals Inc
24/01/202415:01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:PMVPPMV Pharmaceuticals Inc
18/01/202422:01GlobeNewswire Inc.PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash RunwayNASDAQ:PMVPPMV Pharmaceuticals Inc
11/01/202422:18Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PMVPPMV Pharmaceuticals Inc
05/01/202422:01GlobeNewswire Inc.PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage DevelopmentNASDAQ:PMVPPMV Pharmaceuticals Inc
09/11/202314:00GlobeNewswire Inc.PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
12/10/202318:30GlobeNewswire Inc.PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C MutationNASDAQ:PMVPPMV Pharmaceuticals Inc
11/10/202318:00GlobeNewswire Inc.PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL WebinarNASDAQ:PMVPPMV Pharmaceuticals Inc
20/09/202322:05GlobeNewswire Inc.PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsNASDAQ:PMVPPMV Pharmaceuticals Inc
09/08/202314:00GlobeNewswire Inc.PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
12/06/202323:56Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PMVPPMV Pharmaceuticals Inc
09/06/202314:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PMVPPMV Pharmaceuticals Inc
06/06/202322:01GlobeNewswire Inc.PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare ConferenceNASDAQ:PMVPPMV Pharmaceuticals Inc
10/05/202314:00GlobeNewswire Inc.PMV Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
01/05/202312:20Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:PMVPPMV Pharmaceuticals Inc
28/04/202314:05Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:PMVPPMV Pharmaceuticals Inc
28/04/202314:03Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:PMVPPMV Pharmaceuticals Inc
28/04/202314:02Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:PMVPPMV Pharmaceuticals Inc
01/03/202314:06Edgar (US Regulatory)Annual Report (10-k)NASDAQ:PMVPPMV Pharmaceuticals Inc
01/03/202314:00GlobeNewswire Inc.PMV Pharmaceuticals Reports Full Year 2022 Financial Results and Corporate HighlightsNASDAQ:PMVPPMV Pharmaceuticals Inc
01/03/202313:03Edgar (US Regulatory)Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)NASDAQ:PMVPPMV Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PMVP

La tua Cronologia

USOTC
RLBY
Reliability (PK)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network